Literature DB >> 21930869

Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia.

Emilia Cantón1, Javier Pemán, Guillermo Quindós, Elena Eraso, Ilargi Miranda-Zapico, María Álvarez, Paloma Merino, Isolina Campos-Herrero, Francesc Marco, Elia Gomez G de la Pedrosa, Genoveva Yagüe, Remedios Guna, Carmen Rubio, Consuelo Miranda, Carmen Pazos, David Velasco.   

Abstract

A 13-month prospective multicenter study including 44 hospitals was carried out to evaluate the epidemiology of Candida parapsilosis complex candidemia in Spain. Susceptibility to amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole, posaconazole, anidulafungin, caspofungin, and micafungin was tested by the microdilution colorimetric method. A total of 364 C. parapsilosis complex isolates were identified by molecular methods: C. parapsilosis (90.7%), Candida orthopsilosis (8.2%), and Candida metapsilosis (1.1%). Most candidemias (C. parapsilosis, 76.4%; C. orthopsilosis, 70.0%; C. metapsilosis, 100%) were observed in adults. No C. orthopsilosis or C. metapsilosis candidemias occurred in neonates. C. parapsilosis was most frequent in adult intensive care unit (28.8%), surgery (20.9%), and internal medicine (19.7%) departments; and C. orthopsilosis was most frequent in hematology (28.6%), pediatrics (12.0%), and neonatology (11.5%) departments. The geographic distribution of C. orthopsilosis and C. metapsilosis was not uniform. According to CLSI clinical breakpoints, all C. orthopsilosis and C. metapsilosis isolates were susceptible to the nine agents tested. Resistance (MICs > 1 mg/liter) was observed only in C. parapsilosis: amphotericin B, posaconazole, itraconazole, and caspofungin (0.3% each), anidulafungin (1.9%), and micafungin (2.5%). Applying the new species-specific fluconazole and echinocandin breakpoints, the rates of resistance to fluconazole for C. parapsilosis and C. orthopsilosis increased to 4.8% and 0.3%, respectively; conversely, for C. parapsilosis they shifted from 1.9 to 0.6% (anidulafungin) and from 2.5 to 0.6% (micafungin). Our study confirms the different prevalence of C. parapsilosis complex candidemia among age groups: neither C. orthopsilosis nor C. metapsilosis was isolated from neonates; interestingly, C. metapsilosis was isolated only from adults and the elderly. The disparity in antifungal susceptibility among species could be important for therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930869      PMCID: PMC3232769          DOI: 10.1128/AAC.00466-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  55 in total

1.  Phylogenetic relationship and mode of evolution of yeast DNA topoisomerase II gene in the pathogenic Candida species.

Authors:  M Kato; M Ozeki; A Kikuchi; T Kanbe
Journal:  Gene       Date:  2001-07-11       Impact factor: 3.688

2.  Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death.

Authors:  A Viudes; J Pemán; E Cantón; P Ubeda; J L López-Ribot; M Gobernado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-10-31       Impact factor: 3.267

3.  Candida metapsilosis as the least virulent member of the 'C. parapsilosis' complex.

Authors:  Carlotta Francesca Orsi; Bruna Colombari; Elisabetta Blasi
Journal:  Med Mycol       Date:  2010-05-28       Impact factor: 4.076

4.  Detection of seven Candida species using the Light-Cycler system.

Authors:  P Lewis White; Anjali Shetty; Rosemary A Barnes
Journal:  J Med Microbiol       Date:  2003-03       Impact factor: 2.472

5.  National surveillance of fungemia in Denmark (2004 to 2009).

Authors:  Maiken Cavling Arendrup; Brita Bruun; Jens Jørgen Christensen; Kurt Fuursted; Helle Krogh Johansen; Poul Kjaeldgaard; Jenny Dahl Knudsen; Lise Kristensen; Jens Møller; Lene Nielsen; Flemming Schønning Rosenvinge; Bent Røder; Henrik Carl Schønheyder; Marianne K Thomsen; Kjeld Truberg
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

6.  [Changes in the epidemiology of fungaemia and fluconazole susceptibility of blood isolates during the last 10 years in Spain: results from the FUNGEMYCA study].

Authors:  Javier Pemán; Emilia Cantón; Juan José Camarena Miñana; Julia Alcoba Florez; Julia Echeverria; David Navarro Ortega; José Martínez Alarcón; Dionisia Fontanals; Bárbara Gomila Sard; Buenaventura Buendía Moreno; Luis Torroba; Josefina Ayats; Miguel Ángel Bratos Pérez; María Alvarez Fernández; Ferrán Sánchez Reus; Isabel Fernández Natal; Gloria Royo García; Guillermo Ezpeleta; Estrella Martín-Mazuelos; Isabel Iglesias; Antonio Rezusta; Inmaculada Ramírez de Ocariz; Amelia Gómez Nieto
Journal:  Rev Iberoam Micol       Date:  2011-03-03       Impact factor: 1.044

7.  Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2010-12-15       Impact factor: 5.948

8.  Molecular epidemiology and antifungal susceptibility of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis in Taiwan.

Authors:  Yee-Chun Chen; Yu-Hsin Lin; Kuo-Wei Chen; Joanne Lii; Hwa-Jen Teng; Shu-Ying Li
Journal:  Diagn Microbiol Infect Dis       Date:  2010-09-20       Impact factor: 2.803

9.  Characterization of Candida parapsilosis complex isolates.

Authors:  M de Toro; M J Torres; Ruiz Maite; J Aznar
Journal:  Clin Microbiol Infect       Date:  2011-03       Impact factor: 8.067

10.  Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil.

Authors:  S S Gonçalves; C S Amorim; M Nucci; A C B Padovan; M R S Briones; A S A Melo; A L Colombo
Journal:  Clin Microbiol Infect       Date:  2009-08-17       Impact factor: 8.067

View more
  47 in total

1.  Accurate identification of Candida parapsilosis (sensu lato) by use of mitochondrial DNA and real-time PCR.

Authors:  Ana Carolina R Souza; Renata C Ferreira; Sarah S Gonçalves; Guillermo Quindós; Elena Eraso; Fernando C Bizerra; Marcelo R S Briones; Arnaldo L Colombo
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Comparative evaluation of BD Phoenix and vitek 2 systems for species identification of common and uncommon pathogenic yeasts.

Authors:  Brunella Posteraro; Alberto Ruggeri; Elena De Carolis; Riccardo Torelli; Antonietta Vella; Flavio De Maio; Walter Ricciardi; Patrizia Posteraro; Maurizio Sanguinetti
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

3.  Comparison of commercial methods and the CLSI broth microdilution to determine the antifungal susceptibility of Candida parapsilosis complex bloodstream isolates from three health institutions in Rio de Janeiro, Brazil.

Authors:  Maria Helena G Figueiredo-Carvalho; Leonardo S Barbedo; Manoel M E Oliveira; Fábio Brito-Santos; Rodrigo Almeida-Paes; Rosely M Zancopé-Oliveira
Journal:  Mycopathologia       Date:  2014-06-22       Impact factor: 2.574

4.  Microsatellite genotyping clarified conspicuous accumulation of Candida parapsilosis at a cardiothoracic surgery intensive care unit.

Authors:  Magda Diab-Elschahawi; Christina Forstner; Ferry Hagen; Jacques F Meis; Andrea M Lassnig; Elisabeth Presterl; Corné H W Klaassen
Journal:  J Clin Microbiol       Date:  2012-08-08       Impact factor: 5.948

5.  Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis.

Authors:  Julie Autmizguine; Sylvia Tan; Michael Cohen-Wolkowiez; C Michael Cotten; Nathan Wiederhold; Ronald N Goldberg; Ira Adams-Chapman; Barbara J Stoll; P Brian Smith; Daniel K Benjamin
Journal:  Pediatr Infect Dis J       Date:  2018-09       Impact factor: 2.129

6.  Identification of Candida parapsilosis Sensu Lato in Pediatric Patients and Antifungal Susceptibility Testing.

Authors:  Maria Emilia Cattana; Catiana Dudiuk; Mariana Fernández; Florencia Rojas; Liliana Alegre; Susana Córdoba; Guillermo Garcia-Effron; Gustavo Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 7.  Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans.

Authors:  Andrew T Nishimoto; Cheshta Sharma; P David Rogers
Journal:  J Antimicrob Chemother       Date:  2020-02-01       Impact factor: 5.790

Review 8.  The Candida pathogenic species complex.

Authors:  Siobhán A Turner; Geraldine Butler
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-02       Impact factor: 6.915

9.  Isolation and drug susceptibility of Candida parapsilosis sensu lato and other species of C. parapsilosis complex from patients with blood stream infections and proposal of a novel LAMP identification method for the species.

Authors:  Plinio Trabasso; Tetsuhiro Matsuzawa; Renata Fagnani; Yasunori Muraosa; Kenichiro Tominaga; Mariangela Ribeiro Resende; Katsuhiko Kamei; Yuzuru Mikami; Angelica Zaninelli Schreiber; Maria Luiza Moretti
Journal:  Mycopathologia       Date:  2014-12-07       Impact factor: 2.574

10.  Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae.

Authors:  Ana Carolina R Souza; Beth Burgwyn Fuchs; Henrique M S Pinhati; Ricardo A Siqueira; Ferry Hagen; Jacques F Meis; Eleftherios Mylonakis; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.